Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS)

Historical Holders from Q4 2015 to Q3 2025

Symbol
ACRS on Nasdaq
Type / Class
Equity / Common Stock, par value $0.00001 per share
Shares outstanding
108,380,780
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
85,675,311
Holdings value
$162,782,120
% of all portfolios
0.001%
Number of holders
103
Number of buys
40
Number of sells
-47
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BML Investment Partners, L.P. 13.3% $21,802,500 14,250,000 BML Investment Partners, L.P. 31 Dec 2024
VANGUARD GROUP INC 6.15% +31% $9,460,129 +$2,402,369 6,662,063 +34% The Vanguard Group 30 Jun 2025
BlackRock, Inc. 5.1% $7,769,830 5,471,711 BlackRock, Inc. 30 Jun 2025
Adage Capital Management, L.P. 4.87% -34.1% $10,028,474 -$5,554,080 5,278,144 -35.6% Adage Capital Management, L.P. 30 Sep 2025
Rock Springs Capital Management LP 4.7% $7,720,853 5,046,309 Rock Springs Capital Management LP 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 3.5% -32% $5,449,080 -$2,422,176 3,837,380 -30.8% Millennium Management LLC 30 Jun 2025

Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 85,675,311 $162,782,120 -$11,317,612 $1.9 103
2025 Q2 91,862,480 $130,443,350 -$2,093,251 $1.42 95
2025 Q1 92,164,636 $141,009,418 +$2,108,864 $1.53 106
2024 Q4 87,478,919 $216,988,373 +$93,728,957 $2.48 97
2024 Q3 50,891,008 $58,523,068 -$1,742,222 $1.15 76
2024 Q2 52,848,132 $58,129,308 -$1,619,597 $1.1 93
2024 Q1 54,386,842 $67,436,941 -$3,788,067 $1.24 93
2023 Q4 58,449,543 $61,369,526 -$207,123,774 $1.05 102
2023 Q3 70,071,814 $479,974,125 -$28,113,579 $6.85 137
2023 Q2 71,014,841 $736,442,996 +$5,835,766 $10.37 131
2023 Q1 71,610,627 $579,302,266 +$19,605,105 $8.09 148
2022 Q4 65,900,596 $1,037,946,141 -$2,542,115 $15.75 126
2022 Q3 63,675,444 $1,002,225,041 +$5,530,098 $15.74 124
2022 Q2 63,269,555 $883,318,693 +$55,162,166 $13.96 112
2022 Q1 59,295,213 $1,021,908,185 +$59,352,437 $17.24 107
2021 Q4 56,045,310 $814,890,981 -$39,784,690 $14.54 133
2021 Q3 56,785,960 $1,022,155,424 +$15,328,009 $18 126
2021 Q2 56,004,936 $983,410,407 +$20,628,850 $17.56 128
2021 Q1 45,417,666 $1,298,594,000 +$509,363,836 $25.2 95
2020 Q4 31,934,018 $206,591,000 +$27,717,112 $6.47 79
2020 Q3 25,553,008 $65,673,000 -$3,889,513 $2.57 52
2020 Q2 28,456,883 $46,099,261 -$5,512,533 $1.62 56
2020 Q1 32,079,500 $33,361,056 +$3,161,589 $1.04 65
2019 Q4 30,811,789 $58,227,600 +$3,325,295 $1.89 72
2019 Q3 29,070,550 $31,395,961 -$19,214,772 $1.08 76
2019 Q2 35,610,940 $77,957,966 -$16,270,841 $2.19 82
2019 Q1 37,867,320 $227,075,061 -$11,074,522 $5.99 91
2018 Q4 39,079,487 $288,764,092 +$36,606,178 $7.39 95
2018 Q3 29,659,351 $430,705,323 -$29,549,131 $14.52 81
2018 Q2 30,998,695 $618,964,700 +$11,707,281 $19.97 92
2018 Q1 30,570,960 $535,621,157 +$33,812,143 $17.52 100
2017 Q4 28,517,743 $703,264,074 -$10,560,834 $24.66 102
2017 Q3 28,502,689 $696,914,157 +$73,632,695 $25.81 102
2017 Q2 25,609,895 $694,432,125 +$43,716,393 $27.12 101
2017 Q1 23,711,078 $707,195,746 +$74,703,828 $29.82 111
2016 Q4 21,351,804 $579,490,455 +$95,769,317 $27.14 100
2016 Q3 15,510,238 $397,182,894 +$4,351,904 $25.61 59
2016 Q2 15,355,135 $283,613,231 +$13,304,019 $18.47 47
2016 Q1 14,605,233 $276,749,000 +$2,035,314 $18.95 34
2015 Q4 10,288,500 $277,169,982 +$277,169,982 $26.94 33